Ovid Therapeutics Inc
OVID
Get informed when a big investor buys or sells
+ FollowMarket Cap$444.2M
Close$
$-1.53
164.1% downside
Current Fair Value
164.1% downsideOvervalued by 164.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $444.20 Million |
|---|---|
| Enterprise Value | $445.59 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.24 |
| Beta | 0.25 |
| Outstanding Shares | 73,735,606 |
Return
| Return on Equity | -16.43% |
|---|---|
| Return on Assets | -14.87% |
| Return on Invested Capital | -26.45% |
Valuation & Multiples
| P/E Ratio | -4.96 |
|---|---|
| PEG | -2.25 |
| Price to Sales | - |
| Price to Book Ratio | 1.19 |
| Enterprise Value to Revenue | 281.49 |
| Enterprise Value to EBIT | -7.59 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
$-0.12
Average shareholder expectationRevenue Estimate
$64,286
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.08
Average shareholder expectationRevenue Estimate
$17,750
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6691▼ 95.66% |
|---|---|
| Total Calls | 139,300▲ 25.95% |
| Total Puts | 93,200▼ 48.16% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 199.97%▲ 57.48% |
|---|---|
| Total Invested | $396.70M▲ 70.12% |
| Investors Holding | 135▲ 26.00% |
ESG Score
No data
About Ovid Therapeutics Inc
CEO: Jeremy Levin